Literature DB >> 24662136

Lymph node count at inguinofemoral lymphadenectomy and groin recurrences in vulvar cancer.

Heleen J van Beekhuizen1, Maria Auzin, Loes C G van den Einden, Johanna A de Hullu, Jacobus van der Velden, Mark F Wildhagen, Helena C van Doorn.   

Abstract

OBJECTIVE: The objective of the study is to determine the risk factors for groin recurrence (GR) in patients with primary vulvar squamous cell carcinoma (SCC) after inguinofemoral lymphadenectomy (IFL) without lymph node metastases and/or adjuvant chemoradiotherapy.
METHODS: The study is a multicenter retrospective review of clinical and histopathological data of patients with lymph node-negative vulvar SCC who underwent an IFL. Patients with and without GRs were compared to identify risk factors.
RESULTS: In 134 patients, 252 groins were eligible for the analyses--16 patients underwent ipsilateral IFL and 118 patients underwent bilateral IFL. Groin recurrences occurred in 4 (1.6%) of the 252 dissected groins. Besides, 1 patient who underwent ipsilateral IFL had a recurrence in the nonoperated contralateral groin; this groin was left out of analysis. The median number of dissected nodes per groin was 9.8 (range, 1-38) in all patients and 6.5 (range, 5-8) in patients with GR. Multivariate analyses showed that GR was related to poor differentiation (P = 0.04), and node count less than 9 (P = 0.04), no association with age, tumor localization, tumor diameter, focality, invasion depth, or stage was found. Nineteen patients with both low node count and poor differentiation had 19% GRs. Survival analyses showed less favorable survival in patients with poor differentiation.
CONCLUSIONS: The overall risk of developing GR after negative IFL in patients with vulvar SCC is low (1.6% per groin) but significantly higher in patients with tumors with a poor differentiation and lymph node count less than 9 at IFL. A large well-designed prospective study is needed to evaluate closer surveillance in patients at risk.

Entities:  

Mesh:

Year:  2014        PMID: 24662136     DOI: 10.1097/IGC.0000000000000125

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  4 in total

Review 1.  New Directions in Vulvar Cancer Pathology.

Authors:  Anthony Williams; Sheeba Syed; Shireen Velangi; Raji Ganesan
Journal:  Curr Oncol Rep       Date:  2019-08-15       Impact factor: 5.075

2.  Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 1: Model for the Free-Drug Mixture.

Authors:  Simone Perazzolo; Laura M Shireman; Danny D Shen; Rodney J Y Ho
Journal:  J Pharm Sci       Date:  2021-10-19       Impact factor: 3.784

Review 3.  Surgical management of squamous cell vulvar cancer without clitoris, urethra or anus involvement.

Authors:  Alpaslan Kaban; Işık Kaban; Selim Afşar
Journal:  Gynecol Oncol Rep       Date:  2017-02-10

4.  Prognostic value of lymph node ratio in surgically treated cases of vulvar cancer: a tertiary care centre experience.

Authors:  Pabashi Poddar; Shilpa Patel; Ruchi Arora; Chetana Parekh; Pariseema Dave; Sangeetha Amin
Journal:  Obstet Gynecol Sci       Date:  2020-02-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.